Intravenous immune globulin in lysinuric protein intolerance

J Inherit Metab Dis. 1998 Apr;21(2):95-102. doi: 10.1023/a:1005383307100.

Abstract

In addition to systemic manifestations with skeletal, pulmonary, renal, and haematological signs, lysinuric protein intolerance (LPI), a membrane transport defect of cationic amino acids, is often complicated by severe life-threatening immunological manifestations. A 10-year-old boy with LPI who exhibited a severe systemic immunohaematological disease is described here. This patient showed cutaneous lesions similar to the subacute form of systemic lupus erythematosus, severe anaemia and dysproteinaemia, and a marked reduction of circulating T lymphocytes, mainly the CD4+ cells. In vitro bone marrow cell culture studies showed that addition of patient's serum induced macrophage proliferation and inhibited erythroid progenitor cell growth. Treatment with high-dose intravenous immune globulin resolved most of the clinical and laboratory abnormalities.

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Metabolism, Inborn Errors / immunology
  • Amino Acid Metabolism, Inborn Errors / therapy*
  • Arginine / metabolism*
  • Child
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Lysine / metabolism*
  • Male
  • Ornithine / metabolism*

Substances

  • Immunoglobulins, Intravenous
  • Arginine
  • Ornithine
  • Lysine